


Alternar título de la diapositiva

con logo de Agile

Opciones de terapia de primera elección para CCECC R/M

Regimen Name	Regimen Consists of...
EXTREME	Platinum + Fluorouracil + Cetuximab
TPE _x	Taxane + Platinum + Cetuximab
Immune Checkpoint Inhibitor (ICI)	Pembrolizumab ± (Platinum + Fluorouracil)

KEYNOTE-048 Diseño del estudio (NCT02358031)



Resumen de supervivencia general

Population	Interim Analysis ¹ HR (95% CI)	Final Analysis HR (95% CI)
Pembrolizumab + chemotherapy vs EXTREME		
PD-L1 CPS ≥20	—	0.60 (0.45–0.82); <i>P</i> = 0.0004 ^a
PD-L1 CPS ≥1	—	0.65 (0.53–0.80); <i>P</i> < 0.0001 ^a
Total	0.77 (0.63–0.93); <i>P</i> = 0.0034 ^{a,b}	0.72 (0.60–0.87) ^c
Pembrolizumab monotherapy vs EXTREME		
PD-L1 CPS ≥20	0.61 (0.45–0.83); <i>P</i> = 0.0007 ^a	0.58 (0.44–0.78) ^c
PD-L1 CPS ≥1	0.78 (0.64–0.96); <i>P</i> = 0.0086 ^a	0.74 (0.61–0.90) ^c
Total	0.85 (0.71–1.03) ^b	0.83 (0.70–0.99); <i>P</i> = 0.0199 ^d

Efectos adversos relacionados con la inmunidad pueden afectar cualquier sistema orgánico

